Abcam, ab280943, Recombinant human PD-L1 protein (Active)

Size: 50µg / 100µg / 250µg
Recombinant human PD-L1 protein (Active) is a Human Fragment protein in the 19 to 238 aa range with >=95% purity, <= 0.005 EU/µg endotoxin level and suitable for SDS-PAGE, Functional studies, ELISA, mass spectrometry and HPLC. The predicted molecular weight of ab2809432 protein is 25.3 kDa. - Save time and ensure accurate results - use our PD-L1 protein as a control - Optimal protein bioactivity, stability and reproducibility - Available in different sizes to fit your experimental needs
Key facts
Purity:>95% SDS-PAGE,
Endotoxin level:<0.005 EU/µg,
Expression system:HEK 293 cells,
Tags:Tag free,
Applications:sELISA, HPLC, Mass Spec, SDS-PAGE, FuncSSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Biologically active:Yes,
Biological activity:Fully biologically active measured by its ability to inhibit anti-CD3 and anti-CD8 antibody induced T-cell expansion. ED50 for this effect is ≤500 ng/mL with a specific activity of 0.2 x 104 units/mg.,
Accession:Q9NZQ7,
Animal free:Yes,
Carrier free:No,
Species:Human,
Reconstitution:Reconstitute in PBS,
Storage buffer:pH: 7.4Constituents: 10.26% Trehalose, 0.727% Dibasic monohydrogen potassium phosphate, 0.248% Potassium phosphate monobasic

Product details:
Ensure the validity of your result using our recombinant human PD-L1 protein ab280943 as a control.
The ab280943 PD-L1 protein is sourced from HEK293 cells and can be used as a positive control in SDS-PAGE, mass spectrometry and HPLC. Analyze your PD-L1 ELISA data using the ab280943 protein to generate and plot a standard curve.
Check out our protein gel staining guide for SDS-PAGE
Check out our ELISA protocol for more information
Premium Bioactive Protein range
The ab280943 PD-L1 protein is part of the premium bioactive protein range which are ideal for preclinical cell culture and functional studies. These recombinant proteins are of the highest activity, purity, and consistency, meeting rigorous biophysical characterization.
More premium bioactive proteins can be found

Properties and Storage Information:
Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions-Ambient, Appropriate long-term storage conditions-Ambient

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.
Biological function summary
PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.
Pathways
PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.
PD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.